8-K: QT Imaging Reports Q1 2026 Results, Revenue Up 133%

QT Imaging Holdings announced first quarter 2026 financial results, reporting $6.5 million in revenue, a 133% year-over-year increase, alongside key strategic advancements including a new CPT code and loan maturity extension.

Summary

• QT Imaging Holdings reported first quarter 2026 revenue of $6.5 million, a significant increase of 133% compared to $2.8 million in the first quarter of 2025.
• The company shipped 13 Breast Acoustic CT scanners in Q1 2026, up from six in the prior year period.
• Gross margin decreased to 41% in Q1 2026 from 65% in Q1 2025, attributed to the sale of depreciated scanners in the prior year.
• Total operating expenses increased to $5.0 million in Q1 2026 from $2.9 million in Q1 2025, driven by higher compensation and service costs.
• Net loss for Q1 2026 was $3.4 million ($0.25 per share), an improvement from a net loss of $11.1 million ($1.21 per share) in Q1 2025.
• Non-GAAP adjusted EBITDA was $(1.9) million in Q1 2026, compared to $(0.9) million in Q1 2025.
• The company reaffirmed its 2026 revenue guidance of approximately $39 million.
• Key strategic achievements include securing a Category III CPT code for its technology, effective January 2027, and extending the maturity date of its senior secured term loan by two years to March 31, 2029.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, driven by exceptional revenue growth, significant reduction in net loss, and crucial strategic advancements like the CPT code and loan maturity extension, despite some margin compression.

Positives

• Revenue increased by 133% year-over-year to $6.5 million in Q1 2026.
• Scanner shipments more than doubled to 13 units in Q1 2026 compared to six units in Q1 2025.
• Net loss significantly decreased to $3.4 million in Q1 2026 from $11.1 million in Q1 2025.
• Secured a dedicated Category III CPT code (X579T) for its technology, effective January 1, 2027, which is expected to facilitate U.S. reimbursement.
• Extended the maturity date of the senior secured term loan by two years to March 31, 2029, providing increased financial flexibility.
• Received FDA 510(k) clearance for enhancements improving visualization of posterior breast tissue.
• Achieved regulatory clearance in the United Arab Emirates, supporting a multiyear commercial agreement with minimum order quantities totaling over $24 million through 2028.
• Uplisted to The Nasdaq Capital Market.

Negatives

• Gross margin decreased from 65% in Q1 2025 to 41% in Q1 2026, primarily due to the prior year's sale of fully depreciated scanners.
• Total operating expenses increased by approximately 73% year-over-year, from $2.9 million to $5.0 million.
• Non-GAAP adjusted EBITDA worsened from $(0.9) million in Q1 2025 to $(1.9) million in Q1 2026.
• Net cash used in operating activities increased slightly from $3.5 million in Q1 2025 to $3.7 million in Q1 2026.
• Cash, cash equivalents, and restricted cash decreased from $10.5 million at the end of 2025 to $7.0 million at the end of Q1 2026.

Risks

• The ability of the Company to sell and deploy QTIs Breast Acoustic CT Scanner.
• The impact of military actions in the Gulf region on the Company's ability to ship products to that region.
• The ability to extend product offerings into new areas or products.
• The ability to commercialize technology and unexpected occurrences that deter the full documentation and bring-to-market plan for products.
• Trends and fluctuations in the industry, changes in demand and purchasing volume of customers, and unpredictability of suppliers.
• The ability to attract and retain qualified personnel and move product sales to production levels.
• Changes in domestic and foreign business, market, financial, political, and legal conditions.
• Uncertainty of projected financial information and delays caused by factors outside of our control.

Future Outlook

The Company reaffirms its guidance for 2026 revenue to be approximately $39 million, based on expected scanner shipments in the U.S. and worldwide, and initial revenue from the QT Imaging Cloud Platform, in accordance with distribution agreements.

Management Comments

• "We continued to execute during the first quarter, making meaningful progress across commercialization, regulatory execution, and clinical validation."
• "This extension provides the Company with additional financial flexibility as we continue executing on our commercial, clinical, and strategic growth initiatives."
• "We believe QTscan is uniquely positioned as a radiation-free, compression-free, true 3D breast-imaging platform capable of providing quantitative information meant to improve clinical decision making, particularly for women with dense breasts."
• "We remain focused on disciplined execution as we expand adoption of the platform globally."

Industry Context

StockSavvy.ai notes that QT Imaging's strong revenue growth and progress in securing reimbursement pathways (CPT code) are positive indicators in the competitive medical imaging sector, particularly for technologies offering radiation-free alternatives. The company's international expansion also aligns with broader trends of global healthcare market penetration for innovative medical devices.

Comparison to Industry Standards

• The 133% year-over-year revenue growth is significantly higher than the typical growth rates seen in the established medical device industry, which often ranges from single digits to low double digits annually.
• The gross margin of 41% is on the lower end for medical device manufacturers, where margins can often exceed 50-60%, though this is explained by the sale of depreciated assets in the prior year.
• The net loss, while substantial, represents a significant improvement from the previous year, indicating progress towards profitability, a common challenge for early-stage medical technology companies.
• Securing a dedicated CPT code is a critical step for U.S. market adoption and reimbursement, a process that can take years and is a benchmark for new medical technologies aiming for widespread clinical use.

Stakeholder Impact

• Shareholders: Potential for increased valuation due to strong revenue growth, improved net loss, and strategic milestones like CPT code approval and Nasdaq uplisting. However, continued operating losses and cash burn remain a concern.
• Employees: Positive impact from company growth and Nasdaq listing, potentially leading to increased job security and opportunities. Increased operating expenses suggest investment in personnel.
• Customers/Clinicians: Benefit from improved visualization and posterior breast tissue imaging enhancements. The QT Imaging-Olea Viewer and software updates aim to improve workflow and clinical decision-making.
• Distributors/Partners: Supported by committed minimum order quantities in the UAE and the Amended NXC Distribution Agreement in the U.S., indicating continued partnership and sales channel development.

Next Steps

• Continue executing on commercialization, regulatory execution, and clinical validation.
• Leverage the new Category III CPT code for U.S. reimbursement, effective January 2027.
• Expand international presence, particularly in the UAE, supporting the multiyear commercial agreement.
• Continue advancing the technology platform with software improvements and new viewer functionalities.
• Focus on disciplined execution to expand global adoption of the QTscan platform.
• Monitor progress towards the 2026 revenue guidance of approximately $39 million.

Key Dates

Recommendation

The strong revenue growth and strategic wins are highly positive, but the continued increase in operating expenses, worsening adjusted EBITDA, and significant net loss warrant a cautious approach. The company is making progress, but profitability is not yet in sight, and the extended loan maturity comes with a higher interest rate. A 'hold' recommendation reflects the balance between significant positive developments and ongoing financial challenges.

Keywords

QT Imaging, Breast Acoustic CT, Medical Device, Revenue Growth, CPT Code, FDA Clearance, Nasdaq Listing, Financial Results